Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Retained Earnings (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Retained Earnings data on record, last reported at -$3.0 billion in Q4 2025.

  • For Q4 2025, Retained Earnings rose 18.72% year-over-year to -$3.0 billion; the TTM value through Dec 2025 reached -$3.0 billion, up 18.72%, while the annual FY2025 figure was -$3.0 billion, 18.72% up from the prior year.
  • Retained Earnings reached -$3.0 billion in Q4 2025 per PTCT's latest filing, down from $5.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $10.3 million in Q2 2022 and bottomed at -$3.6 billion in Q4 2024.
  • Average Retained Earnings over 5 years is -$1.7 billion, with a median of -$2.2 billion recorded in 2021.
  • Peak YoY movement for Retained Earnings: surged 100.56% in 2022, then plummeted 283703.35% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$24.3 million in 2021, then plummeted by 10842.15% to -$2.7 billion in 2022, then skyrocketed by 99.95% to -$1.3 million in 2023, then tumbled by 283703.35% to -$3.6 billion in 2024, then increased by 18.72% to -$3.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$3.0 billion in Q4 2025, $5.9 million in Q3 2025, and -$2.8 billion in Q2 2025.